

# Orphan Medical Incorporated

[View the current Orphan Medical Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7917-Orphan+Medical+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/7917-Orphan+Medical+Incorporated.html>)

## Contact Details:

**13911 Ridgedale Drive, Suite 475**  
**Minnetonka**  
**MN**  
**55305**  
**United States of America**

Tel: 612 513 6900

Fax:

Email:

Orphan Medical Incorporated is a development stage company, was formed to acquire, develop and market products of high medical value intended to address inadequately treated or uncommon diseases of well-defined patient population treated by health care specialists. A drug has high medical value if it offers a major improvement in the safety or efficacy of patient treatment and has no substantially equivalent substitute.

## Recent Publications by Orphan Medical Incorporated:



- [The clinical development of gamma-hydroxybutyrate \(GHB\).](#)  
*The discovery of gamma-hydroxybutyrate (GHB) over 40 years ago led to its...*3rd September, 2008  
Orphan Medical, Inc., A subsidiary of Jazz Pharmaceuticals, Inc., Palo- Curr Drug Saf. 2006  
Jan;1(1):99-106.
- [Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients.](#)  
*BACKGROUND AND PURPOSE: To measure the effect of the nocturnal...*8th February, 2006  
Orphan Medical, Inc., 13911 Ridgedale Drive Suite 250, Minnetonka, MN- Sleep Med. 2005  
Sep;6(5):415-21. ([DOI Direct Link](#))
- [Pharmacotherapy for cataplexy.](#)  
*A variety of medications representing several major drug classes improve...*29th January, 2005  
Orphan Medical, Inc., Medical Affairs, 13911 Ridgedale Drive, Suite 250,- Sleep Med Rev. 2004  
Oct;8(5):355-66. ([DOI Direct Link](#))
- [The Xyrem risk management program.](#)  
*Sodium oxybate, also known as gamma-hydroxybutyric acid (GHB), was...*13th August, 2004  
Orphan Medical Inc., Minnetonka, Minnesota 55305, USA.- Drug Saf. 2004;27(5):293-306.

- [The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.](#)  
This trial was conducted to evaluate the pharmacokinetics and safety of a...15th June, 2004  
Orphan Medical, Inc., 13911 Ridgedale Drive, Suite 250, Minnetonka, MN- J Clin Pharmacol. 2004 Mar;44(3):253-7. ([DOI Direct Link](#))
- [From club drug to orphan drug: sodium oxybate \(Xyrem\) for the treatment of cataplexy.](#)  
Narcolepsy, a rare disease with a prevalence of 0.05% in the general...11th February, 2004  
Orphan Medical, Inc., Minnetonka, Minnesota 55305, USA.- Pharmacotherapy. 2003 Sep;23(9):1205-9.
- [The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects.](#)  
Sodium oxybate (Xyrem; gamma-hydroxybutyrate) oral solution was recently...15th March, 2003  
Orphan Medical, Inc., 13911 Ridgedale Drive, Suite 250, Minnetonka, MN- J Clin Pharmacol. 2003 Jan;43(1):59-65.
- [Sodium oxybate \(GHB\) for treatment of cataplexy.](#)  
Sodium oxybate (Xyrem; gamma-hydroxybutyrate) oral solution was recently...12th December, 2002  
Orphan Medical, Inc., Minnetonka, Minnesota 55305, USA.- Pharmacotherapy. 2002 Jun;22(6):798-9; discussion 799.

#### Press Releases on Orphan Medical Incorporated:

<a href="#">SIRIUS XM to Broadcast &amp;apos;Doctor Radio Reports: What Every Woman Needs To Know About Mammograms&amp;apos;</a>	20th November, 2009	SIRIUS XM Radio	NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI) today announced that it will broadcast Doctor Radio Reports: What Every Women Needs to Know About Mammograms, an in-depth HAIFA, Israel, November 20 /PRNewswire-FirstCall/ --
<a href="#">Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East</a>	20th November, 2009	Cardio Vascular Medicine Device Corp.	Cardio Vascular Medical Device Corp. (CVSL.OB), <a href="http://www.CVSLMEDICAL.COM">http://www.CVSLMEDICAL.COM</a> , a leading developer of advanced cardiovascular surgery technology, -- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during
<a href="#">H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics</a>	20th November, 2009	Quest Diagnostics Incorporated	WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- There are 18 separate tax hikes in the Reid-Obama healthcare bill. One of them caps the amount that can be deferred in Flexible Spending Accounts (FSAs)
<a href="#">Senate Health Bill Raises Taxes on Families of Special Needs Children</a>	20th November, 2009	Americans for Tax Reform	

[Half of Eligible Patients Do Not Get Aortic Valve Replacement](#)

20th November, 2009

University of Michigan Health System

ANN ARBOR, Mich., Nov. 20 /PRNewswire-USNewswire/ -- Fear about the risk of surgery is among the reasons half of eligible patients are not getting aortic valve replacement surgery, according to a

**BioNews Results for Orphan Medical Incorporated**



- [Aastrom to begin second phase-II trial to treat severe chronic heart failure](#)  
*PharmaBiz: Nov 12 2009 9:25AM Matching: orphan medical*
- [Aastrom To Initiate Second Phase II Clinical Trial For Treatment of Severe Chronic Heart Failure](#)  
*Pharmacy Choice: Nov 12 2009 10:54PM Matching: orphan medical*
- [Medical News: Ikano Therapeutics Receives Orphan Drug Designation For Epilepsy Drug](#)  
*BioFind: Nov 11 2009 2:04PM Matching: orphan medical*
- [Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure](#)  
*Therapeutics Daily: Nov 11 2009 5:47AM Matching: orphan medical*
- [Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure](#)  
*Pharmacy Choice: Nov 11 2009 4:17AM Matching: orphan medical*
- [ABRAXANE\(R\) Receives Orphan Drug Status For The Treatment Of Pancreatic Cancer And Stage IIB-IV Melanoma](#)  
*MediLexicon: Nov 9 2009 12:40AM Matching: orphan medical*
- [Medical News: ABRAXANE\(R\) Receives Orphan Drug Status For The Treatment Of Pancreatic Cancer And Stage IIB-IV Melanoma](#)  
*BioFind: Nov 8 2009 12:43PM Matching: orphan medical*
- [Medical News: ABRAXANE\(R\) Receives Orphan Drug Status For The Treatment Of Pancreatic Cancer And Stage IIB-IV Melanoma](#)  
*BioFind: Nov 8 2009 12:43PM Matching: orphan medical*
- [Written Requests Issued](#)  
*FDA: Nov 6 2009 2:07PM Matching: orphan medical*
- [Medical News: The Creation Of A New Niche Specialty Pharmaceutical Company Focused On Rare Diseases - With Strong Cash Flow Generation And Growth Potential](#)  
*BioFind: Nov 5 2009 3:00PM Matching: orphan medical*
- [Medical News: The Creation Of A New Niche Specialty Pharmaceutical Company Focused On Rare Diseases - With Strong Cash Flow Generation And Growth Potential](#)  
*BioFind: Nov 5 2009 2:59PM Matching: orphan medical*
- [Micromet, Inc. Reports Third Quarter 2009 Financial Results](#)  
*Therapeutics Daily: Nov 5 2009 1:21PM Matching: orphan medical*
- [FDA Expands Agent's Orphan Drug Status](#)  
*MedPage Today: Nov 5 2009 8:59PM Matching: orphan medical*
- [Micromet, Inc. Reports Third Quarter 2009 Financial Results](#)  
*Street Insider: Nov 5 2009 12:28PM Matching: orphan medical*
- [Micromet, Inc. Reports Third Quarter 2009 Financial Results](#)  
*NewsBlaze: Nov 5 2009 12:09PM Matching: orphan medical*

## Orphan Medical Incorporated Clinical Trials:



- [Safety and Efficacy of Xyrem Oral Solution \(Sodium Oxybate\) Compared With Placebo in Narcoleptic Patients](#)

## Orphan Medical Incorporated Patents:



- 7572605- [Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers](#)
- 7262219- [Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy](#)
- 7015200- [Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers](#)
- 6780889- [Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy](#)
- 6472431- [Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy](#)
- 6210666- [Truncated .alpha.-galactosidase A to treat fabry disease](#)
- 5990162- [Method for treatment of fibromyalgia and chronic fatigue syndrome](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

